Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-07-04
DOI
10.1093/jac/dkac184
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)
- (2021) Pranita D Tamma et al. CLINICAL INFECTIOUS DISEASES
- Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia
- (2021) Ignacio Martin-Loeches et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016
- (2020) Shu-Chen Kuo et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia
- (2020) Luzelena Caro et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centers
- (2020) Elizabeth B. Hirsch et al. Journal of Global Antimicrobial Resistance
- Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)
- (2020) Matteo Bassetti et al. Open Forum Infectious Diseases
- Treatment of extended-spectrum β-lactamases infections
- (2020) Matteo Bassetti et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens
- (2020) Michael A. Pfaller et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Molecular Characterization of Baseline Enterobacterales and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial
- (2020) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study)
- (2020) Marta Hernández-García et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Application of Next-Generation Sequencing for Characterization of Surveillance and Clinical Trial Isolates: Analysis of the Distribution of β-lactamase Resistance Genes and Lineage Background in the United States
- (2019) Rodrigo E Mendes et al. Open Forum Infectious Diseases
- Comparative Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from United States Hospitals
- (2019) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients
- (2019) B. Gutiérrez-Gutiérrez et al. CLINICAL MICROBIOLOGY AND INFECTION
- Comparison of ceftazidime-avibactam and Ceftolozane-Tazobactam in vitro activities when tested against gram-negative Bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017–2018)
- (2019) Helio S. Sader et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Update on Molecular Epidemiology and Treatment Options
- (2019) Gisele Peirano et al. DRUGS
- Laces out Dan! The role of tazobactam based combinations for invasive ESBL infections in a post-MERINO world
- (2019) Jason M. Pogue et al. EXPERT OPINION ON PHARMACOTHERAPY
- Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
- (2019) Marin H Kollef et al. LANCET INFECTIOUS DISEASES
- In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016)
- (2019) James A. Karlowsky et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Ceftolozane/tazobactam: place in therapy
- (2018) Daniele Roberto Giacobbe et al. Expert Review of Anti-Infective Therapy
- Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013–2015)
- (2018) M.A. Pfaller et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
- (2018) Evelina Tacconelli et al. LANCET INFECTIOUS DISEASES
- Treatment of Infections with OXA-48 producing Enterobacteriaceae
- (2018) Adam Stewart et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance
- (2018) Patrick N. A. Harris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Carbapenem-Sparing Therapy for Extended-Spectrum β-Lactamase–Producing E coli and Klebsiella pneumoniae Bloodstream Infection
- (2018) Mary K. Hayden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The ideal patient profile for new beta-lactam/beta-lactamase inhibitors
- (2018) Philippe Montravers et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Antimicrobial activity of ceftolozane–tazobactam tested against gram-negative contemporary (2015–2017) isolates from hospitalized patients with pneumonia in US medical centers
- (2018) Cecilia G. Carvalhaes et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Recommendations and guidelines for the treatment of pneumonia in Taiwan
- (2018) Chih-Chen Chou et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia
- (2017) Antoni Torres et al. EUROPEAN RESPIRATORY JOURNAL
- The ecology of extended-spectrum β-lactamases (ESBLs) in the developed world
- (2017) Yohei Doi et al. JOURNAL OF TRAVEL MEDICINE
- Ceftolozane–tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013–2015)
- (2017) M.A. Pfaller et al. Journal of Global Antimicrobial Resistance
- Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
- (2016) Andre C. Kalil et al. CLINICAL INFECTIOUS DISEASES
- Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections
- (2016) Matteo Bassetti et al. Expert Review of Anti-Infective Therapy
- Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae : a pooled analysis of Phase 3 clinical trials
- (2016) Myra W. Popejoy et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
- (2016) Valerio Del Bono et al. Virulence
- Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study
- (2014) Frédéric Frippiat et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)
- (2013) David J. Farrell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
- (2012) G. Chandorkar et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing
- (2012) Anton Bankevich et al. JOURNAL OF COMPUTATIONAL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More